The Effects of Clofibrate on Neonatal Jaundice: A Systematic Review

Abstract

**Background:** Neonatal jaundice is a prevalent disease that causes many complications, including kernicterus and even death. Previous studies have shown that clofibrate as an aryloxy isobutyric acid derivate can be effectively applied for the treatment of neonatal jaundice. Thus, this review was carried out to investigate the effects and mechanism of action of clofibrate on neonatal jaundice.

**Methods:** The keywords such as “Clofibrate” in combination with “Neonatal jaundice” or “Neonatal hyperbilirubinemia” or “Newborn Jaundice” were used to search for relevant publications indexed in the Institute for Scientific Information (ISI), Scopus, PubMed, and Google Scholar databases. Finally, after reviewing the studies, 24 papers were included in this study.

**Results:** Results showed that the processes of albumin-bound bilirubin transfer to the hepatocytes, hepatic uptake, and storage via ligandin, hepatic conjugation via uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1), conjugation into the bile via MRP2 represent the main action mechanism of clofibrate that turns it into the bilirubin conjugates and expels it from the bile. Besides, clofibrate has been shown to reduce the level of Total Serum Bilirubin (TSB) in infants even at a dosage of 25 mg/kg without leaving side effects.

**Conclusions:** The results of this review revealed that clofibrate effectively reduces TSB in short-term usage and can even have a promising effect at the dosage of 25 mg/kg in full-term infants. Most studies have shown this property over a short period in term infants, and there is no evidence about long-term usage in this regard.

**Keywords:** Clofibrate, hyperbilirubinemia, neonatal jaundice, newborn jaundice

Introduction

Neonatal jaundice is one of the prevalent and life-threatening disorders in neonates.[1] Neonatal jaundice is prevalent among up to 80% of premature infants and 60% of term infants.[2,3] This disease develops during the first few days of birth and is caused by several factors such as uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1), polymorphism, low birth weight, small for gestational age, neonatal sepsis, hematoma absorption, maternal-fetal ABO blood group incompatibility, metabolic diseases, liver diseases, etc.[4] If it isn’t treated in due time, it will result in dangerous and sometimes permanent complications such as neurological disorders, cerebral palsy, auditory nerve damage, chore atetoid, and bilirubin encephalopathy,[5,6] and interferes with maternal-infant emotional interaction and breastfeeding.[7] Additionally, this multi-risk factor disease is considered as a reason for most cases of newborn hospitalization imposing significant health burdens in low-income and middle-income countries.[8]

The main mechanism of jaundice is based on the imbalance between bilirubin production and conjugation. Bilirubin in the form of unconjugated bilirubin is transferred in the blood. The liver changes bilirubin into a conjugated form which is expelled from the body along with bile.[9] Very high levels of unconjugated bilirubin can cause kernicterus and consequently neurotoxic complications like cerebral palsy and deafness.[10,11] So if the jaundice is not treated properly as soon as possible, then it causes a lot of complications.[1] Currently, various treatments are applied for the treatment of neonatal jaundice in medical settings among which phototherapy is the mainstay of these methods.[12] Although, phototherapy has low complications in short-term treatment, it causes squints and abnormal developmental performance in newborns,[13] interference with maternal-infant interaction, imbalance in thermal environment and water loss, electrolyte disturbance hypocalcemia, the...
disorder of circadian rhythms, as well as the development of the bronze baby syndrome.\[14\]-[16] Besides, the health care providers must consider a set of items such as different wavelengths, total doses, intensities, and commencement threshold for achieving the best effectiveness and safety.\[17\] Therefore, in addition to the phototherapy administered, as the current treatment to reduce the complications and treatment duration, other treatments, such as medication therapy should be considered. Therefore, the increasing desire to use drugs has been developed as an adjunct therapy. On the other hand, there is limited strong evidence about the use of pharmacotherapy such as clofibrate, human albumin, intravenous immunoglobulin, herbal therapy, ursodeoxycholic acid, and phenobarbital treatment in neonatal jaundice.\[12\],\[18\]-\[21\] Clofibrate is an arylxoyisobutyric acid derivative used in the treatment of hypertriglyceridemia and dyslipidemia.\[13\] However, previous studies showed that clofibrate is effective in the treatment of neonatal jaundice.\[14\],\[22\] Therefore, this study was conducted to investigate the effects and mechanism of clofibrate action on neonatal jaundice.

**Materials and Methods**

To conduct this study, the keywords of interest were searched using EndNote software. The keywords included “Clofibrate” in combination with “Neonatal jaundice” or “Neonatal hyperbilirubinemia” or “Newborn Jaundice” that were used to search for relevant publications indexed in the Institute for Scientific Information (ISI), Scopus, and PubMed databases. (For ISI and PubMed databases, keywords were searched by EndNote software.)

Given the insufficiency of the studies in the ISI and PubMed databases, the Google scholar database was searched. Among 862 results obtained concerning the mentioned keywords, 6 papers (except duplications) were added to the bank of the study. A standard form was designed consisting of items such as author, the title or purpose of the study, intervention, gestational age, birth weight, age at enrolment (day), Total Serum Bilirubin (TSB) at admission, clofibrate dosage (mg/kg), side effects (at hospitalization period and follow-up), outcomes (including the mean TSB, duration of phototherapy, and duration of hospitalization), journal name and article number. The full text of the papers matched the purpose of the study was recorded in the form and entered into the study with agreement of co-authors. A search was conducted by two separate researchers. The inclusion criteria were clinical trials performed on neonatal jaundice, as well as the studies that showed positive effects on neonatal jaundice. The papers which had non-positive effects, full texts of which were not accessible, review papers, non-English or non-Persian language papers, and those which were not related to the aim of this study were excluded after all the authors reached an agreement. Finally, 24 papers were included in the study [Figure 1].

For quality assessment, the protocol of RCTs was considered and the methodological quality of the primary

---

**Figure 1: Flowchart of the study design** (This flowchart illustrates how the papers were selected for final analysis.)

**Figure 2: Bilirubin clearance mechanism of clofibrate in the liver**
### Table 1: The effects of clofibrate treatment on neonatal jaundice

| References                  | Gestational age                      | Birth weight (kg) | Age at enrolment (day) | TSB at admission (mg/dl) | Direct and indirect bilirubin (mg/dl) | Clofibrate dose (mg/kg) | Side effects | TSB level (mg/dl) | Direct and indirect bilirubin (mg/dl) | Duration of phototherapy | Duration of hospitalization |
|-----------------------------|--------------------------------------|-------------------|------------------------|--------------------------|--------------------------------------|-------------------------|--------------|------------------|---------------------------------------|--------------------------|-------------------------------|
| Mohammadzadeh et al.[23]   | Full-term (37-41 weeks of gestation) | 3260±481          | 9±4                    | 23.3±3.36                | 0.92±0.52 (Direct)                   | 100                     | No           | Reduced (After 12, 24, and 48 h) | No change reported for direct bilirubin | Reduced                  | -                             |
| Zahedpasha et al.[24]       | Not reported                          | 3110.8±453.9      | 6.02±2.09              | 17.85±2.09               | 0.79±0.12 (Direct)                   | 100                     | No           | Reduced (After 48 and 72 h)      | No change reported for direct bilirubin | -                         | Reduced                      |
| Eghbalian et al.[14]        | Full-term                             | >2500             | Majority 2-3           | 20.85±3.6                | 20.35±3.5 (Indirect)                | 100                     | No           | Reduced (After 12 and 24 h)      | Reduced for indirect bilirubin | Reduced                  | Reduced                      |
| Moslehi et al.[25]          | Full-term                             | 2543±548          | 5.2±1.9                | 17.63±1.4                | 0.46±0.20 (Direct)                   | 25/50                   | No           | Reduced (After 12 and 24 h)      | -                       | Reduced                      |
| Zahedpasha et al.[26]       | Full-term                             | 3133±456          | 6.0±2.9                | 17.85±2.09               | 0.79±0.11 (Direct)                   | 100                     | No           | Reduced (After 48 and 72 h)      | No change reported for direct bilirubin | -                         | Reduced                      |
| Badeli et al.[27]           | Full-term                             | 3171±278          | 5.3±1.8                | 18.4±1.6                 | -                                    | 100                     | No           | Reduced (After 12, 24, and 36 h) | -                       | Reduced                      |
| Mohammadzadeh et al.[28]    | Preterm (31.5±1.5 weeks of gestation) | 1369±201          | 31.48±1.52             | 5.9±2.4                  | -                                    | 100                     | No           | Reduced (After 24 h)             | -                       | Reduced                      |
| Zahedpasha et al.[29]       | Full-term                             | 3258±479          | 18.0±1.9               | 5.1±2.3                  | 0.78±0.18 (Direct)                   | 100                     | No           | Reduced (After 16, 24, and 48 h) | No change for direct bilirubin       | Reduced                  | Reduced                      |
| Ghotbi et al.[30]           | Full-term                             | 3211.5±425        | 4.2±0.15               | 17.4±0.93                | -                                    | 100                     | No           | Reduced (After 12, 24, and 48 h) | -                       | Reduced                      |
| Mohammadzadeh et al.[31]    | Preterm (31.5±1.5 weeks of gestation) | 2114±328          | 9.2±5.4                | 21.1±5.2                 | 0.51±0.26 (Direct)                   | 100                     | No           | No change                        | No change                | Reduced                      |
| Sakha et al.[32]            | Preterm (34-37 weeks of gestation)    | 2359±535          | 6.1±2.9                | 19.8±2.4                 | 0.82±0.41 (Direct)                   | 100                     | No           | Reduced (After 48 h)             | -                       | Reduced                      |
| Sharafi et al.[33]          | Full-term                             | 3129±431          | 6.7±2.9                | 17.3±1.5                 | -                                    | 50                      | No           | Reduced (After 24 and 48 h)      | -                       | Reduced                      |
| Alipour et al.[34]          | Full-term                             | 3245±189          | 6±2.56                 | -                        | -                                    | 100                     | No           | Reduced (After 24 h)             | -                       | Reduced                      |
| Eghbalian et al.[35]        | -                                    | -                 | 3.31±1.84              | -                        | 50/25                                | No                      | No           | Reduced (After 12, 24, and 36 h) | Reduced for indirect bilirubin | Reduced                  | Reduced                      |
| Fallah et al.[36]           | Full-term                             | 3197±370          | 4.85±1.96              | 19.52±2.64               | -                                    | 50                      | No           | Reduced (After 12, 24, and 48h)  | Reduced for indirect bilirubin | Reduced                  | Reduced                      |
| Habibi et al.[22]           | Full-term                             | 3081±319          | 3.25±1.04              | 20.65±2.41               | 0.45±0.48 (Direct)                   | 100                     | -            | Reduced (After 24 and 48 h)      | -                       | Reduced                      |

Contd...
Table 1: Contd...

| Reference | Gestational age   | Birth weight (kg) | Age at enrollment (day) | TSB at admission (mg/dl) | Direct and Clofibrate Side effects | Direct and Clofibrate dose (mg/kg) | Direct and Clofibrate TSB level (mg/dl) | Duration of phototherapy admission (day) | Duration of direct bilirubin conjugation (%) | Duration of indirect bilirubin conjugation (%) | Duration of hospitalization admission (day) |
|-----------|-------------------|-------------------|-------------------------|--------------------------|-----------------------------------|----------------------------------|----------------------------------------|--------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|
| Abadi et al. [37] | Full-term | 2500-4000 | 4.06±4.04 | 17.9±1.01 | Reduced (After 24 h) | - | Reduced (After 24 h) | - | Reduced (After 24 h) | - | Reduced (After 24 h) | - |
| Hamidi et al. [38] | Full-term | 2500-4000 | 6.12±2.88 | 19.88±2.30 | No | - | No | - | No | - | No | - |
| Poursakha [39] | Full-term | 3240±380 | 6.12±2.48 | 16.49±2.64 | No | - | No | - | No | - | No | - |
| Kumar et al. [40] | Full-term | 2780±253.5 | 4.05±4.14 | 18.3±2.05 | Reduced (After 24 h) | - | Reduced (After 24 h) | - | Reduced (After 24 h) | - | Reduced (After 24 h) | - |

Table 1: Summary of included studies.

*Outcome considered based on comparing the P value between control and treatment groups. **Neonates were affected by glucose-6-phosphate dehydrogenase (G6PD) deficiency.***

In the reviewed studies, complications were mostly evaluated by clinical observations which could be considered as a limitation of the clinical studies. Thus, it is recommended to perform laboratory tests and biochemistry examinations (according to the side effects) in future studies to obtain more valuable results. A high degree of heterogeneity among the trials resulted from different TSB levels at baseline, studies was assessed including research design, study sample, participation rates, sources of bias, data collection, follow-up or attrition rates, and data analysis. The studies with the minimum clinical trials requirements were included in the study.

**Results**

Finally, 24 papers were found to meet the inclusion criteria and were selected for the study. Most important variables influencing the outcome of the studies and clofibrate treatment are presented in Table 1.

**Discussion**

This study was conducted to investigate the effects and action mechanism of clofibrate on neonatal jaundice. Clofibrate modulates the gene involved in lipid homeostasis and as an aryloxyisobutyric acid derivate can stimulate peroxisomeproliferator-activated receptors, as a result of which the conjugation with glucuronic acid is catalyzed by UGT1A1. Eventually, bilirubin conjugates are excreted into the bile through the canalicular ATP-dependent transporter MRP2. Taken together, clofibrate increases the excretion of albumin-bound bilirubin through enhancing the enzymatic steps in hepatocytes [47] [Figure 2].

Besides, clofibrate increases the stimulation of glucuronosyltransferase and augments bilirubin conjugation and excretion, causing a significant increase in the bilirubin clearance and reduction of unconjugated hyperbilirubinemia. Therefore, these changes also reduce the duration of phototherapy and hospitalization in neonates and diminish the complications attributed to them. Although clofibrate acts as an antilipidemic drug and causes several complications (such as vomiting, nausea, gastrointestinal problems, loose stools, leucopenia, transient cholestasis, muscle cramping, fatigue, pruritus, alopecia, renal failure, abnormal liver function) (16,49-54) the reviewed studies showed that, the dose of 25-100 mg/kg and short-time administration of clofibrate has not exerted any complication during the treatment and follow-up periods. Lipid and unconjugated bilirubin can conjoint each other and bond to the albumin. Therefore, changes in bilirubin amounts must be adjusted by considering the lipid profile alteration. In this regard, lipids are one of the most important macronutrients, which are necessary for cell growth and development in newborns, so the long-term administration of clofibrate can impair organ development and growth [55,56].

In the reviewed studies, complications were mostly evaluated by clinical observations which could be considered as a limitation of the clinical studies. Thus, it is recommended to perform laboratory tests and biochemistry examinations (according to the side effects) in future studies to obtain more valuable results. A high degree of heterogeneity among the trials resulted from different TSB levels at baseline,
limitation in geological regions (the majority of the trials were carried out in Asia which conceals the effects of genetic factors), lack of using the placebo, and consequently lack of blinding in the control group and unclear allocation was among other limitations of the reviewed studies. On the other hand, hemolytic disease (ABO incompatibility of Rh) and congenital anomaly of infants were considered as exclusion criteria or there was rare number of studies conducted in this area. Therefore, conducting such studies can indicate clear results and address its optimal therapeutic dose in infants with hemolytic diseases.[57]

Conclusion
The results of this review revealed that clofibrate effectively reduces TSB in short-term usage and can even have a promising effect at the dosage of 25 mg/kg in full-term infants. Larger RCTs (complying with all principles of the design) along with longer follow-up and considering hemolytic disease and blood transfusion are needed to elaborate more on the issue.

Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

Received: 21 Jul 20 Accepted: 22 Dec 20
Published: 19 Jan 22

References
1. Ullah S, Rahman K, Hedayati M. Hyperbilirubinemia in neonates: Types, causes, clinical examinations, preventive measures and treatments: A narrative review article. Iran J Public Health 2016;45:558-68.
2. Rennie J, Burman-Roy S, Murphy MS. Neonatal jaundice: Summary of NICE guidance. BMJ 2010;340:c2409.
3. Porter ML, Dennis BL. Hyperbilirubinemia in the term newborn. Am Fam Phys 2002;65:599-606.
4. Babaei H, Parham S. Risk factors of severe hyperbilirubinemia in neonates undergoing exchange transfusion in Imam Reza Hospital Kermanshah-Iran, during 2012 to 2016. Int J Pediatri 2018;6:8061-72.
5. Davutoglu M, Garipardic M, Guler E, Karabiber H, Erhan D. The etiology of severe neonatal hyperbilirubinemia and complications of exchange transfusion. Turk J Pediatri 2010;52:163-6.
6. Das S, van Landeghem FKH. Clinico pathological spectrum of bilirubin encephalopathy/kernicterus. Diagnostics (Basel) 2019;9:24.
7. Waite WM, Taylor JA. Phototherapy for the treatment of neonatal jaundice and breastfeeding duration and exclusivity. Breastfeed Med 2016;11:180-5.
8. Romero HM, Ringer C, Leu MG, Beardsley E, Kelly K, Fesmeyer MD, et al. Neonatal jaundice: Improved quality and cost savings after implementation of a standard pathway. Pediatrics 2018;141:e20161472.
9. Mitra S, Rennie J. Neonatal jaundice: Aetiology, diagnosis and treatment. Br J Hosp Med (Lond) 2017;78:699-704.
10. Rasul CH, Hasan MA, Yasmin F. Outcome of neonatal hyperbilirubinemia in a tertiary care hospital in Bangladesh. Malays J Med Sci 2010;17:40-4.
11. Slusher TM, Zamora TG, Appiah D, Stanke JU, Strand MA, Lee BW, et al. Burden of severe neonatal jaundice: A systematic review and meta-analysis. BMJ Paediatr Open 2017;1:e000105-e.
12. Wan A, Mat Daud S, Teh SH, Choo YM, Kutty FM. Management of neonatal jaundice in primary care. Malays Fam Phys 2016;11:16-9.
13. Drew JH, Marriage K, Bayle VV, Bajraszewski E, McNamara JM. Phototherapy, Short and long-term complications. Arch Dis Child 1976;51:454-8.
14. Eghbalian F, Pourhossein A, Zandevakili H. Effect of clofibrate in non-hemolytic indirect hyperbilirubinemia in full term neonates. Indian J Pediatri 2007;74:1003-6.
15. Peinado-Acevedo JS, Chacon-Valenzuela E, Rodriguez-Moncada LL. [Bronze baby syndrome, an unpredictable complication of phototherapy: A case report]. Biomedica 2018;38:15-8.
16. Xiong T, Qu Y, Cambier S, Mu D. The side effects of phototherapy for neonatal jaundice: What do we know? What should we do? Eur J Pediatri 2011;170:1247-55.
17. Woodgate P, Jardine LA. Neonatal jaundice: Phototherapy. BMJ Clin Evid 2015;2015:0319.
18. Monsef A, Eghbalian F, Rahimi N. Comparison of purgative manna drop and phototherapy with phototherapy treatment of neonatal jaundice: A randomized double-blind clinical trial. Osong Public Health Res Perspect 2019;10:152.
19. Raeisi R, Heidari-Soureshjani S, Asadi-Samani M, Luther T. A systematic review of phytotherapies for newborn jaundice in Iran. Int J Pharm Sci Res 2017;8:1953-8.
20. Gharehbaghi MM, Sani AM, Refeey M. Evaluating the effects of different doses of ursodeoxycholic acid on neonatal jaundice. Tur J Pediatri 2020;62:424-30.
21. Honar N, Saadi EG, Saki F, Pishva N, Shakibazad N, Teshnizi SH. Effect of ursodeoxycholic acid on indirect hyperbilirubinemia in neonates treated with phototherapy. J Pediatri Gastroenterol Nutr 2016;62:97-100.
22. Habibi M, Mahyar A, Ayazi P, Ahmadabadi F, Javadi A. The effect of clofibrate on hyperbilirubinemia of term neonates. Acta Med Iran 2012;50:21-5.
23. Mohammadzadeh A, Farhat A, Iranpour R. Effect of clofibrate in jaundiced term newborns. Indian J Pediatri 2005;72:123-6.
24. Zahedpasha Y, Naderi S, Ahmadpour M. Effect of clofibrate plus phototherapy on bilirubin concentration of Hormozgan Medical Journal.2006:10:207-12.
25. Moslehi M, Pishva N. Determination of effect of low dose vs moderate dose clofibrate on decreasing serum bilirubin in healthy term neonates. Iran J Pediatri 2007;17:108-12.
26. Zahedpasha Y, Ahmadpour-Kacho M, Hajjahmad M, Naderi S. Effect of clofibrate in jaundiced full-term infants: a randomized clinical trial. Arch Iran Med 2007;10:349-53.
27. Badiei HR, Sharaifi R, Sajedi SA. The effect of clofibrate on neonatal hyperbilirubinemia in uncomplicated jaundice. Iran J Pediatri 2008;18:20-4.
28. Mohammadzadeh A, Sh FA, Jafarzadeh M, Mirzarahimi M, Esmaeili H, Amiri R. Prophylactic effect of clofibrate in low birth weight neonates hyperbilirubinemia. J Chin Clin Med 2008;3.
29. Zahedpasha Y, Ahmadpour-Kacho M, Hajjahmad M, Naderi S, Kamali AA. Efficacy of clofibrate on severe neonatal jaundice associated with glucose-6-phosphate dehydrogenase deficiency (a randomized clinical trial). Southeast Asian J Trop Med Public Health 2008;39:557-61.
30. Ghotbi F, Tghiloo M, Gashb A. The effect of clofibrate on neonatal jaundice. Pejouesh dar Pezeshki (Research in
Eghbalian, et al.: Clofibrate on neonatal jaundice worldwide. Indian J Pediatr 2012;79:253-5.

45. Mancuso C. Bilirubin and brain: A pharmacological approach. Neuropharmacology 2017;118:113-23.

46. Sticova E, Jirsa M. New insights in bilirubin metabolism and their clinical implications. World J Gastroenterol 2013;19:6398-407.

47. Cuperus FJ, Hafkamp AM, Hulzebos CV, Verkade HJ. Pharmacological therapies for unconjugated hyperbilirubinemia. Curr Pharm Des 2009;15:2927-38.

48. Gholitabar M, McGuire H, Remnie J, Manning D, Lai R. Clofibrate in combination with phototherapy for unconjugated neonatal hyperbilirubinemia. Cochrane Database Syst Rev 2012;12:CD009017.

49. Brun S, Carmona MC, Mampel T, Vinas O, Giralt M, Iglesias R, et al. Activators of peroxisome proliferator-activated receptor-alpha induce the expression of the uncoupling protein-3 gene in skeletal muscle: A potential mechanism for the lipid intake-dependent activation of uncoupling protein-3 gene expression at birth. Diabetes 1999;48:1217-22.

50. Steiner A, Weisser B, Vetter W. A comparative review of the adverse effects of treatments for hyperlipidaemia. Drug Saf 1991;6:118-30.

51. Erkul I, Yavuz H, Ozel A. Clofibrate treatment of neonatal jaundice. Pediatrics 1991;88:1292-4.

52. Pokroy N, Ress S, Gregory MC. Clofibrate-induced complications in renal disease: A case report. S Afr Med J 1977;52:806-8.

53. Pierides AM, Alvarez-Ude F, Kerr DN. Clofibrate-induced muscle damage in patients with chronic renal failure. Lancet 1975;2:1279-82.

54. Eghbalian F, Monsef F, Alam Ghomi N, Monsef A. Effect of low versus moderate dose of clofibrate on serum bilirubin in healthy term neonates with indirect hyperbilirubinemia. Iran J Med Sci 2013;38:349-50.

55. Torkaman M, Saburi A. What is important about the effect of clofibrate on neonatal hyperbilirubinemia? Acta Med Iran 2013;51:139-40.

56. Martínez N, White V, Kurtz M, Higa R, Capobianco E, Jawerbaum A. Activation of the nuclear receptor PPARalpha regulates lipid metabolism in foetal liver from diabetic rats: Implications in diabetes-induced foetal overgrowth. Diabetes Metab Res Rev 2011;27:35-46.

57. Torabi Z, Eskandarzadeh A, Ahmadiafsbahr A. The effect of clofibrate with phototherapy on full-term newborns with non-hemolytic jaundice. Iran Red Crescent Med J 2013;15:285-6.